-

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day.

Investors can register for the conference by contacting their ROTH Capital Partners representative.

About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less™ gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Program, please visit www.allurion.com.

Contacts

Investor Contact
investors@allurion.com

Industry:

Allurion Technologies, Inc.

NYSE:ALUR
Release Versions
English
$Cashtags
$ALUR

Contacts

Investor Contact
investors@allurion.com

More News From Allurion Technologies, Inc.

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. “The obesity epidemic is growing, and patients are in need of mo...

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating...

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and...
Back to Newsroom